

28th October 2020

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001	National Stock Exchange of India, Exchange Plaza, 5 th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051
Scrip Code: BSE – AJANTPHARM 532331	Scrip Code: NSE AJANTPHARM EQ

Sub.: Notice of the meeting of Board of Directors of Ajanta Pharma Limited (the “Company”) to consider buyback of equity shares having face value of Rs. 2 (Rupees Two Only) each (“Equity Shares”)

Dear Sirs/Madam,

Ref.: Prior intimation pursuant to Regulation 29(1)(b) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”)

This is with reference to our letter dated 23rd October 2020, informing you about the Board Meeting of the Company scheduled to be held on Tuesday, 3rd November 2020 (“**Board Meeting**”), to consider, inter-alia the unaudited consolidated and financial results for the quarter and half year ended 30th September 2020 and interim dividend.

Pursuant to Regulation 29(1)(b) of Listing Regulations, we hereby inform you that, at the aforesaid Board Meeting, the Board of Directors will also consider a proposal for buy-back of the Equity Shares of the Company including matters related /incidental thereto (“**Buyback**”) and any other matter as the Board of Directors of the Company may decide during the course of the meeting.

You are requested to please take a note of the same.

Thanking you,

Yours faithfully,

Gaurang Shah

VP – Legal, Corporate Affairs & Company Secretary